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BACKGROUND: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor antibody in
metastatic colorectal cancer (CRC). KRAS mutation analysis is usually performed on primary tumour tissue because metastatic tissue
is often not available. However, controversial data are available on the concordance of test results between primary tumours and
corresponding metastases. We assessed the concordance of KRAS mutation status in a study of 305 primary colorectal tumours and
their corresponding liver metastases.
METHODS: Patients with histologically confirmed CRC who underwent surgical resection of the primary tumour and biopsy or surgical
resection of the corresponding liver metastasis were included. KRAS mutation analysis was performed for codons 12 and 13.
RESULTS: KRAS mutation was detected in 108 out of 305 primary tumours (35.4%). In 11 cases (3.6%), we found a discordance
between primary tumour and metastasis: 5 primary tumours had a KRAS mutation with a wild-type metastasis, 1 primary tumour was
wild type with a KRAS mutation in the metastasis, and in 5 cases the primary tumour and the metastasis had a different KRAS mutation.
CONCLUSION: We observed a high concordance of KRAS mutation status of 96.4% (95% CI 93.6–98.2%) between primary colorectal
tumours and their corresponding liver metastases. In only six patients (2.0%; 95% CI 0.7–4.2%), the discordance was clinically
relevant. In this largest and most homogenous study to date, we conclude that both primary tumours and liver metastases can be
used for KRAS mutation analysis.
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Recent advances in specific signalling pathways of cancer cells
have introduced targeted therapy into treatment regimes for
patients with metastatic colorectal cancer (CRC) (Tol and Punt,
2010). Cetuximab and panitumumab are monoclonal antibodies
that bind to the extracellular domain of the epidermal growth
factor receptor (EGFR). They inhibit ligand-induced stimulation of
several intracellular signalling pathways, such as RAS/RAF/MAPK
and phosphoinositide-3 pathway, which results in decreased
stimulation of cell cycle progression, proliferation, angiogenesis,
and stimulation of apoptosis (Scaltriti and Baselga, 2006). The
KRAS oncogene is currently the most relevant molecular
biomarker that predicts the response to EGFR-targeted therapy
in CRC. An oncogenic mutation in KRAS leads to constitutive
activation of the RAS/RAF signalling pathway independent from
EGFR activation by binding of the ligand (Benvenuti et al, 2007).
KRAS mutations occur in approximately 38% of colorectal
tumours and involve codon 12 and 13 in 496% of cases (Oliveira
et al, 2004). Metastatic CRC patients with tumours harbouring a
KRAS mutation are resistant to treatment with anti-EGFR
antibodies, showing lower response rates, decreased progression-
free survival, and overall survival compared with patients with
KRAS wild-type tumours (Karapetis et al, 2008; Tol et al, 2009; Van
Cutsem et al, 2009). Therefore, the European Medicines Agency
and the Food and Drug Administration have restricted the use of
anti-EGFR antibodies in metastatic CRC to patients with KRAS
wild-type tumours.
Cetuximab and panitumumab have shown efficacy both as
monotherapy (Amado et al, 2008; Karapetis et al, 2008) and in
combination with chemotherapy (Tol et al, 2009; Van Cutsem et al,
2009) in patients with KRAS wild-type metastatic CRC. Never-
theless, even among patients with KRAS wild-type tumours, the
majority of patients do not respond to anti-EGFR therapy. Efficacy
of anti-EGFR therapy was suggested to be further restricted to
patients with BRAF wild-type tumours (Di Nicolantonio et al,
2008). An additional explanation for the suboptimal response rates
to anti-EGFR antibodies in patients with KRAS wild-type tumours
is discordance of KRAS mutation status between primary colo-
rectal tumours and corresponding metastases. In the early
dissemination model, tumour cells depart the primary lesion
before the acquisition of a fully malignant phenotype to undergo
new mutations and metastatic growth at a distant site (Klein,
2009). According to this model, a discordance in mutation status
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sbetween primary tumours and metastases may occur, and as a
consequence the mutation status of the primary tumour might not be
adequate to predict the response of metastases to anti-EGFR treatment.
Current data on the concordance in KRAS mutation status
between primary colorectal tumours and metastases are conflict-
ing. Five studies showed a 100% concordance of KRAS mutation
status in primary CRC and corresponding metastases (Losi et al,
1992; Suchy et al, 1992; Zauber et al, 2003; Weber et al, 2007;
Etienne-Grimaldi et al, 2008). In contrast to these data, others have
reported a discordance of KRAS mutation status in primary
tumours and metastatic sites, with an overall discordance observed
in 4–32% of the patients (Oudejans et al, 1991; Al-Mulla et al,
1998; Albanese et al, 2004; Oliveira et al, 2007; Artale et al, 2008;
Santini et al, 2008; Cejas et al, 2009; Garm Spindler et al, 2009;
Loupakis et al, 2009; Molinari et al, 2009; Perrone et al, 2009;
Baldus et al, 2010; Italiano et al, 2010). These controversial results
are probably due to the fact that these studies were underpowered
with a small number of patients, and included a wide variety of
metastatic sites. Therefore, it is still uncertain whether the
evaluation of KRAS mutation status in the most commonly
available primary tumour correctly reflects the KRAS mutation
status of corresponding metastasis. This is highly relevant given
the large number of CRC patients as well as the potential toxicity
and costs of anti-EGFR therapy.
We assessed the concordance in KRAS mutation status in
primary tumours and their corresponding liver metastases in an
adequately powered study of 305 CRC patients.
PATIENTS AND METHODS
Patient selection
Patients with histologically confirmed CRC who underwent
surgical resection of the primary tumour and biopsy or surgical
resection of the corresponding liver metastasis were included in
this analysis. Results were obtained from archived material of three
large pathology laboratories and from material collected from the
CAIRO2 study, a large multicentre trial of the Dutch Colorectal
Cancer Group (Tol et al, 2009).
In patients with a discordance of KRAS mutation status between
the primary tumour and metastasis, additional blocks of the
primary tumour were obtained to exclude heterogeneity within the
tumour. Lymph node metastases present at the time of diagnosis
were also acquired in these patients.
Tumour DNA preparation
Formalin-fixed paraffin-embedded tissue blocks were cut at 4mm
thickness and stained with haematoxylin and eosin (HE). The
presence of tumour tissue was marked by a pathologist. Subse-
quently the blocks were cut at 20–40mm thickness and micro
dissected for DNA extraction. Tumour tissue was dissolved in 200ml
lysis buffer (QIAamp DNA Micro Kit, Qiagen, Venlo, The Netherlands)
and incubated with proteinase K overnight at 561C for two nights.
DNA was extracted according to the manufacturer’s protocol
(QIAamp DNA Micro Kit, Qiagen), and DNA concentration was
determined at 260nm using the Nanodrop 26 ND-1000 spectro-
photometer (Nanodrop Technologies Inc., Wilmington, NC, USA).
KRAS mutation analysis
For KRAS mutation analysis, exon 2 (codon 12 and 13) was
amplified using a 50ml reaction mixture containing 0.2mm forward
(50-TGTAAAACGACGGCCAGTAGGCCTGCTGAAAATGACTG-30)
and reverse (50-CAGGAAACAGCTATGACCTGGATCATATTCG
TCCACAAAA-30) primers (Invitrogen, Breda, The Netherlands);
dATP, dCTP, dGTP and dTTP (GE Healthcare, Zeist, The
Netherlands) at 0.2mM each; 50mM KCl; 10mM Tris-HCl (pH
8.3); 2.5mM MgCl2; 1U AmpliTaq Gold polymerase (Applied
Biosystems, Nieuwkerk a/d IJsel, The Netherlands) and 50ng of
template DNA. The PCR conditions were as follows: 941C for
10min; 921C for 1min, 601C for 1min, 721C for 1min (40 cycles);
and 721C for 10min.
All PCR products were purified with the MultiScreen HTS,
96 well Filtration System (Millipore, Carrigtwohill, Ireland).
Subsequently, the purified products were sequenced using
fluorescently labelled terminators (BigDye Terminators (v 1.1);
Applied Biosystems, Foster City, CA, USA) with both M13-forward
and M13-reverse sequencing primers. The sequencing products
were analysed on an ABI 3730 DNA Analyser (Applied Biosystems)
and the data analysis was performed using Sequencing Analysis
Software Sequencing Analysis Software v5.3.1 with KBTM Base-
caller. Sequence results were scored by visual inspection of the
chromatograms (Applied Biosystems).
Statistical analysis
We considered a discordance level of 5% or more to be clinically
relevant, that is, leading to substantial change in routine clinical
practice. To exclude such level of discordance under the assumption
that the true discordance was 2.5% or less, we set the sample size at
304 paired samples. With this sample size, the precision in the
estimated percentage of discordance was 2.5% (i.e., s.e. 1.25, half-
width of the 95% confidence interval equal to 2.5%).
The comparison of patient and primary tumour characteristics
between patients with KRAS wild-type and KRAS mutant primary
tumours was done using Wilcoxon’s rank sum test or w
2 for
numerical or categorical variables, respectively. Differences in
KRAS mutation status between the primary tumour and corre-
sponding metastasis were analysed by calculating the percentage of
concordance, and (clinically relevant) discordance, together with
the corresponding Clopper–Pearson 95% confidence intervals.
Differences were considered to be statistically significant when the
P-value was below 0.05. All statistical tests were two-sided.
RESULTS
Patient characteristics
We analysed KRAS codon 12 and 13 mutations in 320 matched
primary colorectal tumours and liver metastases. The tumour cell
percentages in all primary tumours and metastases were above
30%. We failed to obtain a KRAS mutation status in 15 patients;
therefore our further analyses were performed in 305 paired
samples. Patient characteristics are shown in Table 1.
KRAS mutation and histopathological parameters
A total of 108 patients (35.4%) had a KRAS mutation in the
primary tumour; of which 37 patients had a Gly12Asp mutation, 28
patients a Gly12Val mutation, 14 patients a Gly13Asp mutation,
10 patients a Gly12Cys mutation, 7 patients a Gly12Ser mutation,
7 patients a Gly12Ala mutation, 3 patients a Gly12Arg mutation, 1
patient a Gly12Asp and Gly12Ala mutation and 1 patient a
Gly12Phe mutation (Table 2). Histopathological characteristics of
the primary tumour were comparable between patients with and
without a KRAS mutation (Table 1).
Concordance of KRAS status in primary tumours and
corresponding liver metastases
In 294 patients (96.4%; 95% CI 93.6–98.2%), the same KRAS
mutation status was obtained from the primary tumour and the
corresponding liver metastasis. In 11 patients (3.6%; 95% CI 1.8–
6.4%), of which 7 had synchronous metastases at diagnosis and 4
developed metachronous metastases, we found a discordance
KRAS mutation status in liver metastases
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sbetween primary tumours and metastases. Five patients had a
KRAS mutation in the primary tumour and not in the liver
metastasis. Only one patient had a wild-type status of the primary
tumour, while the metastasis showed a KRAS mutation. In five
patients, the primary tumours had different KRAS mutations
compared with the metastases. One of these patients had two
primary tumours. Both primary tumours had the same KRAS
mutation (Gly13Asp), while the liver metastasis had a different
KRAS mutation (Gly12Ser). In another patient, the primary
tumour had a double mutation (Gly12Asp/Gly12Val) and the
Table 1 Distribution of tumour characteristics according to KRAS status of the primary tumour
Overall,
n¼305
KRAS mutation,
n¼108
KRAS wild type,
n¼197 P-value
Age 0.20
Median (IQR) 64 (57–70) 65 (58–71) 64 (57–70)
Gender 0.37
Male 191 (62.6%) 64 (59.3%) 127 (64.5%)
Female 114 (37.4%) 44 (40.7%) 70 (35.5%)
Metastases presentation 0.45
Synchronous 169 (55.4%) 63 (58.3%) 106 (53.8%)
Metachronous 136 (44.6%) 45 (41.7%) 91 (46.2%)
Tumour location 0.63
Colon 167 (54.8%) 59 (54.6%) 108 (54.8%)
Rectum 54 (17.7%) 16 (14.8%) 38 (19.3%)
Rectosigmoid 80 (26.2%) 32 (29.6%) 48 (24.4%)
Unknown 4 (1.3%) 1 (0.9%) 3 (1.5%)
Histopathological subtype 0.12
Adenocarcinoma 271 (88.9%) 90 (83.3%) 181 (91.9%)
Adenocarcinoma with muc. component 21 (6.9%) 10 (9.3%) 11 (5.6%)
Mucinous adenocarcinoma 8 (2.6%) 5 (4.6%) 3 (1.5%)
Unknown 5 (1.6%) 3 (2.8%) 2 (1.0%)
Differentiation grade 0.21
Good 33 (10.8%) 13 (12.0%) 20 (10.2%)
Moderate 196 (64.3%) 65 (60.2%) 131 (66.5%)
Poor 52 (17.0%) 17 (15.7%) 35 (17.8%)
Unknown 24 (7.9%) 13 (12.0%) 11 (5.6%)
T stage 0.62
T1 4 (1.3%) 2 (1.9%) 2 (1.0%)
T2 20 (6.6%) 9 (8.3%) 11 (5.6%)
T3 231 (75.7%) 81 (75.0%) 150 (76.1%)
T4 36 (11.8%) 11 (10.2%) 25 (12.7%)
Unknown 14 (4.6%) 5 (4.6%) 9 (4.6%)
N stage 0.10
N0 114 (37.4%) 46 (42.6%) 68 (34.5%)
N1 87 (28.5%) 31 (28.7%) 56 (28.4%)
N2 86 (28.2%) 26 (24.1%) 60 (30.5%)
Unknown 18 (5.9%) 5 (4.6%) 13 (6.6%)
Number of lymph nodes examined 0.28
Median (IQR) 10 (6–15) 10 (6–13) 10 (6–16)
Number of lymph node metastases 0.15
Median (IQR) 1 (0–4) 1 (0–3) 1 (0–4)
Abbreviation: IQR¼interquartile range.
Table 2 Distribution of KRAS mutation types
Codon 12/13
Patients with KRAS
mutation (n,% )
Gly12Asp 37 (34%)
Gly12Val 28 (26%)
Gly13Asp 14 (13%)
Gly12Cys 10 (9%)
Gly12Ser 7 (6%)
Gly12Ala 7 (6%)
Gly12Arg 3 (3%)
Gly12Phe 1 (1%)
Gly12Asp + Gly12Ala 1 (1%)
Primary
tumour
196 WT 196 WT
98 MT 98 MT
Liver
metastasis
5 MT
type X
5 MT
type Y
5 WT 5 MT
1 WT 1 MT
A
B
C
Figure 1 Overall concordance of the KRAS mutation status between primary
tumour and liver metastasis (A), discordance without clinical impact (B), and
discordance with clinical impact (C). Abbreviations: WT, wild type; MT, mutation.
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smetastasis had a Gly12Asp mutation (Figure 1, Table 3). Taken
together, the observed discordance was clinically relevant in only
six patients (2.0%; 95% CI 0.7–4.2%).
Subsequent analyses in patients with a discordance of
KRAS status
Several tests were performed to exclude bias of the test results.
First, the HE coupes of all patients with a discordant KRAS
mutation status between the primary tumour and liver metastasis
were revised. The primary tumours and liver metastases had a
mean tumour cell percentage of 65 and 60%, respectively.
Subsequent independent reanalysis of the KRAS mutation status
resulted in the same discordances.
Second, several mutation analyses were performed on different
areas of the tumour and from different tumour blocks in order to
establish possible tumour heterogeneity. Two patients showed
heterogeneity of KRAS status within the primary tumour. One of
these patients demonstrated two areas with a Gly12Asp mutation
and one area with wild-type status, of which the latter resembled
the liver metastasis. The other patient showed two different KRAS
mutations within the same tumour, of which one is concordant
with the liver metastasis (Table 3).
Third, 6 of the 11 patients with discordant results did have
lymph nodes metastases at the time of diagnosis. KRAS mutation
testing of all lymph nodes separately revealed overall concordant
KRAS status between lymph node metastases and the primary
tumour in three patients. The KRAS status of the lymph nodes in
the other three patients showed heterogeneity, of which at least one
lymph node metastases showed a different KRAS status compared
with the primary tumour. However, this explains the discordance
between the primary tumour and liver metastasis only in one
patient (Table 3).
DISCUSSION
This is the first adequately powered study in CRC that compares
KRAS mutation status between primary tumours and their
corresponding liver metastases. We showed that tissue from the
primary tumour can reliably be used for KRAS mutation testing in
order to select patients for anti-EGFR therapy.
We observed a concordant KRAS mutation status in 96.4% of
305 paired samples of colorectal tumours and liver metastases.
However, the difference in KRAS status was not clinically relevant
in 5 of the 11 patients with discordant results, because both
primary tumour and metastasis had a different KRAS mutation.
Given the high statistical power of our analysis, we were able to
obtain a highly accurate estimate of the level of discordance that
enabled us to conclude that the level of discordance was 2.0%. The
high rate of concordance is in agreement with the notion that
KRAS mutations are considered as early driving events in CRC
progression, and associated with the growth of small adenoma to
clinically significant size (Vogelstein et al, 1988). Therefore, KRAS
mutation status is expected to be equal in both primary tumours
and metastases (Klein, 2009).
The previously reported lower concordance levels between
primary tumours and metastases are most likely due to bias caused
by false-negative results in underpowered studies. We calculated
that 304 paired cases were needed to reliably exclude a rate of
discordance of 45%, while previous studies included only 10 to
Table 3 Patients with a discordant KRAS status between primary tumour and liver metastasis. Multiple blocks of primary tumour tissue and lymph node
metastases were tested when available
KRAS status
primary tumour
KRAS status
2nd tumour
KRAS status lymph
node metastasis
KRAS status
liver metastasis
1 Gly12Ala — LN 1: Gly12Ala WT
LN 2: Gly12Ala
LN 3: Gly12Ala
2 Gly12Asp — — WT
Gly12Asp
WT
3 Gly12Cys — — WT
4 Gly12Asp — LN 1: Gly12Asp WT
Gly12Asp LN 2: Gly12Asp
Gly12Asp LN 3: Gly12Asp
Gly12Asp LN 4: Gly12Asp
LN 5: WT
5 Gly12Ser — — WT
6 WT — — Gly12Cys
7 Gly12Asp — LN 1: WT Gly12Ala
LN 2: WT
LN 3: WT
8 Gly13Asp Gly13Asp LN 1: Gly13Asp Gly12Ser
9 Gly12Ser — — Gly12Ala
10 Gly12Cys — LN 1: Gly12Asp Gly12Asp
Gly12Asp LN 2: Gly12Asp
LN 3: Gly12Asp
LN 4: Gly12Asp
LN 5: Gly12Asp
LN 6: WT
11 Gly12Asp/Gly12Val — LN 1: Gly12Val Gly12Asp
LN 2: Gly12Val
LN 3: Gly12Val
LN 4: Gly12Asp
LN 5: Gly12Asp
LN 6: Gly12Asp
LN 7: Gly12Asp
Abbreviation: WT¼wild type.
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s110 patients (Table 4). Moreover, in these studies metastases of
different sites were compared with the primary tumour. As the
molecular patterns may differ between metastatic sites (Klein,
2009), more reliable results are obtained when KRAS mutation
status is tested more rigorously for each metastatic site. The liver is
the predominant site of metastases in the majority of metastatic
CRC patients; therefore the results of our large series of 305 liver
metastases provide a solid reference for clinical decision making as
to anti-EGFR therapy. Another issue is the fact that KRAS testing is
technically not as straightforward as is often assumed. Several
quality assurance systems are now in place, and the first ‘round
robin’ test indicates that at least 30% of the experienced pathology
laboratories fail to pass the threshold level of the quality assurance
programs (Bellon et al, 2011). Other important facts about KRAS
testing are the correct evaluation of the amount of tumour tissue in
the sample and the sensitivity of testing methods. In a previous
study, we demonstrated in 4500 samples that both sequencing
and real-time PCR are reliable methods (Tol et al, 2010).
A discordant KRAS status between the primary tumour and
metastasis was observed in a small number of patients (3.6%). In
these cases, tumour cells may have departed the primary lesions
before the acquisition of a fully malignant phenotype to undergo
somatic mutations or deletions at a distant site (Klein, 2009).
Another explanation for the discordant results may be hetero-
geneity of KRAS status within the primary tumour, although this
was the case in only a small number of patients. Finally, a
discordance may in theory be explained by metastases from a non-
detected second primary.
Previously published data showed that a considerable fraction
(25%, Table 4) of colorectal lymph node metastases does not
resemble the primary tumour in terms of KRAS mutation status. In
5 of the 25 lymph node metastases that we tested the KRAS status
was not concordant with the primary tumour, which is consistent
with the literature (Table 4). Therefore, lymph node metastases do
not seem suitable for determination of the KRAS mutation status
of colorectal carcinomas. Discordance in KRAS mutation status
might be due to clonal selection during the process of metastasis,
however, heterogeneity in lymph node metastases could explain
this discordance in only one patient.
Eight different KRAS mutation types were observed in our study,
of which Gly12Asp showed the highest frequency. Five patients
(1.6%) harboured different KRAS mutation types in the primary
tumour compared with the metastases. This confirms the findings
of Cejas et al (2009) and Albanese et al (2004), who reported a
small number of patients (4 and 7%, respectively) with different
mutation types between primary tumours and metastases. A
different KRAS mutation type between primary lung adenocarci-
nomas and corresponding lymph node metastases was also
observed in only 1% of the patients (Schmid et al, 2009).
Currently, all patients with a KRAS mutation are excluded from
treatment with anti-EGFR antibodies, independently of the
mutation type. However, a recent paper indicated that codon 13
mutated tumours may be sensitive to cetuximab treatment
(De Roock et al, 2010). As we observed a low frequency in KRAS
mutation type discrepancies between primaries and metastases,
this is not of clinical importance in selecting patients for anti-
EGFR therapy.
In conclusion, we demonstrated a high level of concordance of
96.4% between primary tumours and liver metastases, which for
clinical purposes to select CRC patients for anti-EGFR therapy was
even higher with 98%. The implication of these results for general
oncology practice is that both tissue of primary tumour or liver
metastasis may be used for KRAS mutation testing. The results of
our study are only valid for liver metastases and cannot be
extrapolated to other metastatic locations. Furthermore, we
demonstrated that discordance of test results between primary
Table 4 Overview of studies providing data on KRAS status of primary tumour and related metastasis
Author
study Year
No.
of pts
Analysed
metastatic site Method
KRAS
mutation
in PT (%)
KRAS
mutation in
PT, WT in M
KRAS
WT in PT,
mutation in M
Total
percentage of
discordance
Albanase 2004 30 Liver SSCP analysis 14 (47%) 5/14 (36%) 4/16 (25%) 9/30 (30%)
Al-Mulla 1998 26 Liver ASO/direct seq 10 (38%) 2/10 (20%) 3/16 (19%) 5/26 (19%)
31 Lymph node ASO/direct seq 10 (32%) 1/10 (10%) 5/21 (24%) 6/31 (19%)
Artale 2008 48 Diverse, 81% liver Direct seq 11 (23%) 1/11 (9%) 2/37 (5%) 3/48 (6%)
Baldus 2010 20 Visceral metastasis Direct seq 9 (45%) 1/9 (11%) 1/11 (9%) 2/20 (10%)
55 Lymph node Direct seq 29 (53%) 15/29 (52%) 2/26 (8%) 17/55 (31%)
Cejas 2010 93 Liver Direct seq 30 (32%) 1/30 (3%) 4/63 (6%) 5/93 (5%)
17 Lung Direct seq 10 (59%) 1/10 (10%) 1/7 (14%) 2/17 (12%)
Etienne-Grimaldi 2008 48 Liver biopsy PCR-RFLP 16 (33%) 0 (0%) 0 (0%) 0 (0%)
Italiano 2009 59 Not specified Seq 23 (39%) 1/23 (4%) 2/36 (6%) 3/59 (5%)
Losi 1992 19 Local recurrence Multiplex-ASPCR 12 (63%) 0 (0%) 0 (0%) 0 (0%)
16 Metastasis, 38% liver Multiplex-ASPCR 13 (81%) 0 (0%) 0 (0%) 0 (0%)
Loupakis 2009 43 Liver Seq Not mentioned 0 (0%) 2/* 2/43 (5%)
Molinari 2009 37 Diverse, 74% liver Seq 16 (43%) 2/16 (13%) 1/21 (5%) 3/37 (8%)
15 Lymph node Seq 8 (53%) 0 (0%) 0 (0%) 0 (0%)
Oliveira 2006 28 Lymph node Not mentioned 18 (64%) 2/18 (11%) 7/10 (70%) 9/28 (32%)
Oudejans 1991 31 Liver and lung Hybridization 14 (45%) 1/14 (7%) 1/17 (6%) 2/31 (6%)
Perrone 2008 10 Diverse, mainly liver Direct seq 2 (20%) 1/2 (50%) 1/8 (13%) 2/10 (20%)
Santini 2008 99 Diverse, 80% liver Seq 38 (38%) 3/38 (8%) 1/61 (2%) 4/99 (4%)
Garm Spindler 2009 31 Not specified qPCR 11 (35%) 2/11 (18%) 0/20 (0%) 2/31 (6%)
Suchy 1992 58 Autopsy material, not specified Dot-blot hybridization 15 (26%) 0 (0%) 0 (0%) 0 (0%)
Weber 2006 36 Liver Seq 14 (39%) 0 (0%) 0 (0%) 0 (0%)
Zauber 2003 42 Diverse, 93% lymph
node, 5% liver
SCCP analysis + seq 22 (52%) 0 (0%) 0 (0%) 0 (0%)
Overall 892 All sites All methods 345/849 (41%) 39/345 (11%) 35/504 (7%) 76/892 (9%)
276 Liver All methods 84/233 (36%) 8/84 (10%) 11/149 (7%) 21/276 (8%)
129 Lymph nodes All methods 65/129 (50%) 18/65 (28%) 14/64 (22%) 32/129 (25%)
Abbreviations: ASO¼allele-specific oligonucleotide; ASPCR¼allele-specific polymerase chain reaction; M¼metastasis; pts¼patients; PT¼primary tumour; qPCR¼
quantitative PCR; RFLP¼restriction fragment length polymorphism; SSCP¼single strand conformational polymorphism; seq¼sequencing. *Total number of cases not specified.
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stumour and metastases cannot account for the failure rate of anti-
EGFR therapy in patients with KRAS wild-type tumours. Therefore,
novel predictive markers in addition to KRAS and BRAF mutation
status are warranted.
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